![](/img/cover-not-exists.png)
1510TiPThe GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors
Garralda, E, van Hoef, M, Ochsenreither, S, Gianni, L, Lorusso, D, Fiedler, W, Keilholz, U, Klinghammer, K, Dicke, C, Kebenko, M, Matos, I, Tabernero, J, Raspagliesi, F, Del Conte, G, Habel, B, BaumeiVolume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy292.131
Date:
October, 2018
File:
PDF, 72 KB
english, 2018